Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD2936 + AZD8205 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD2936 | AZD-2936|AZD 2936|Rilvegostomig | PD-L1/PD-1 antibody 132 TIGIT Antibody 20 | AZD2936 is a bispecific antibody that targets T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and PD-1 (PDCD1), which potentially leads to increased T-lymphocyte antitumor activity, tumor cell killing, and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2022;10). | |
| AZD8205 | AZD 8205|AZD-8205|Puxitatug Samrotecan | AZD8205 is a an antibody-drug conjugate (ADC) comprising a B7-H4 targeted antibody linked to a topoisomerase inhibitor, which potentially leads to apoptosis of B7-H4-expressing tumor cells and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1765). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05123482 | Phase Ib/II | AZD2936 + AZD8205 AZD2936 + AZD8205 + Saruparib AZD8205 AZD8205 + Saruparib AZD8205 + AZD9574 AZD2936 + AZD8205 + AZD9574 | A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies | Recruiting | USA | POL | NLD | ITA | HUN | GBR | ESP | CAN | BEL | AUS | 5 |